Kornimate/medical-research-clean huggingface dataset:
effects of weight loss on nutritional mediated hormone secretion

Conditions: Weight Loss; Hormone Disturbance; Weight Gain

Summary: investigative trial with aim of 1. the description of the hormonal and metabolic response to meals containing different compositions of macronutrients 2. the metabolic response to these test meals in dependance of the hepatic and muscular insulin sensitivity and abdominal adipose tissue and 3. effects of a weight loss on the hormonal response to these test meals containing different compositions of macronutrients primary endpoint: glucagon-like-peptide 1 (glp-1), glucose dependent insulinotropic peptide (gip) and ghrelin response to a nutritive stimulation characterized by different nutritional composition secondary endpoints: * differences of substrate utilization depending on the nutritive composition * effects of different hepatic and muscular insulin sensitivity as well as impact of visceral fat mass on the hormonal and metabolic response * effect of weight loss on the hormonal and metabolic response to different test meals study procedure: after primary characterization 50 probands (male and female) will receive 3 different test meals within a randomised (meal order) controlled trial. the three different test meals differ in nutritional composition. during consumption of the test meal a characterization of the endogenous hormonal response and appetite behaviour is performed. a nutritional counselling is performed according to the guidelines of the german nutrition society (dge) to ensure a stable nutritive behaviour in the three days before the test meal administration. after analysis of the hormonal response to these 3 different testmeals follows a weight reduction period over 3 months. afterwards reevaluation of the probands (again administration of 3 different test meals over a period of 3 weeks) will be performed. principal aim of the study: gain of information leading to the understanding of the hormonal regulation of food intake. the individual variability shall be determined with the aim of an identification of patient groups which show various intensities of the responses to different macronutrients.


Eligibility criteria:
inclusion criteria: * bmi\>27 kg/m2 * given written informed consent exclusion criteria: * type 2 diabetes patients treated by insulin or drugs influencing incretin levels * lack of health insurance * weight changes \> 5 kg in the past 2 months * pregnancy, breastfeeding * patients with: * severe heart failure * impaired hepatic or renal function * disturbed coagulation (biopsies will not be taken in those subjects) * infection, malabsorption * severe hypertension * cancer within the last 5 years * eating disorders or any other psychiatric condition that would interact with the trial intervention * any other endocrine disorder * changes of smoking habits or diets within the last 3 months prior to study inclusion \*other severe chronic diseases
oral complications in hematological malignancies

Conditions: Hematologic Malignancy

Summary: the aim of this study was to evaluate the prevalence and types of oral complications found in patients diagnosed with haematological malignancy

oral lesions can be the first presentation of hematological malignancy. dentists occasionally are the first healthcare provider that detect oral signs related to a systemic condition and thus contribute to the early diagnosis of the disease 1. oral health can impact the progression and the outcome of haematological malignancy patients', many patients may suffer from oral infections that might affect hospital stay, treatment cost and patient prognosis 2. the oral manifestations of patients with hematological malignancy can occur due to the disease itself or as a consequence of treatment 3. anemia (paleness of mucosa), coagulation disorder, oral petechiae or ecchymosis, spontaneous gingival bleeding and oral infection (ulcers and overgrowth) may be an oral manifestation of a hematologic malignancy either at diagnosis or during follow up as well as in relapse 4. the treatment of hematologic malignancy includes chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (hsct). malignant cells are the target of antineoplastic drugs, but the oral epithelium and other cells with high mitotic rates are usually affected by the treatment. chemotherapy and the conditioning regimen for hsct have many adverse effects on the oral tissues depending on the type and dosage of medications 4. oral mucositis, a common side effect of chemotherapy, causes severe pain, which is only relieved by opioids. mucositis may appear as a generalized erythema and evolve into painful pseudomembranous ulcers. neutropenia and thrombocytopenia are also common adverse effects of treatment, leaving patients more susceptible to oral bleeding, infections, and ulcerations. oral mucosa pigmentation can also occur as an adverse effect of treatment 5. considering these factors and lack of existing information, a study was designed to investigate the prevalence of oral complications problems occurring in a population of hematological malignancy patients in assiut university hospital.

Eligibility criteria:
inclusion criteria: * all newly diagnosed patients elder than 18 years with hematological malignancy start from january 1st 2022 to january 1st 2023 including acute myeloid leukemia acute lymphoblastic leukemia chronic myeloid leukemia chronic lymphoblastic leukemia non-hodgkin lymphoma hodgkin lymphoma multiple myeloma exclusion criteria: * patient younger than 18 years old patients previously diagnosed patients refused to participate in our study
the prevalence of sacroiliac joint dysfunction in patients with lumbar disc hernia

Conditions: Lumbar Disc Herniation; Sacroiliac Joint Dysfunction

Summary: in this study evaluated the prevalence of sacroiliac joint dysfunction in patients with lumbar disc hernia and examined the variations in clinical parameters cause by this combination.

two hundred thirty-four patients already diagnosed with lumbar disc hernia were included in the study. during the evaluation, sacroiliac joint dysfunction was investigated using specific tests, pain levels with a visual analog scale, and the presence of neuropathic pain using the leeds assessment of neuropathic symptoms and signs pain scale. other clinical assessments were performed using the beck depression inventory, health assessment questionnaire, and tampa kinesiophobia scale. positivity in three out of six provocation tests was adopted as a criterion for sacroiliac joint dysfunction. sample size a power analysis using the formula n= t2pq / d2 was performed to determine the sample size. based on those data the investigators concluded that a minimum of 174 and a maximum of 322 patients would be required to achieve significant results, and 234 patients were enrolled. statistical analysis the study data were expressed as mean plus standard deviation (sd) for constant variables values and as number and percentage for categoric variables. the chi-square test was used to analyze categoric variables. results were evaluated at a 95% confidence interval at a significance level of p˂0.05. the analysis was performed on statistical package for the social sciences (spss) for windows 16.0 software. the strengthening the reporting of observational studies in epidemiology (strobe) guideline has been implemented in this manuscript.

Eligibility criteria:
inclusion criteria: * between 20 - 60 years old * diagnosis of lumbar disc herniation * to have sufficient cognitive level to fill clinical evaluation forms * the patient agreed to participate in the study exclusion criteria: * lumbar pain, the etiology of which was suspected to be inflammatory in character * structural vertebral deformity or fracture * the severe and progressive neurological deficit * a history of severe psychiatric disease * substance and/or alcohol dependence, with uncontrolled diabetes mellitus (dm), malignancy, spinal infection * a history of vertebral surgery * pregnancy

Keywords: disc hernia dysfunction lumbar sacroiliac joint
inspiratory muscular training

Conditions: Heart Failure

Summary: objectives: to evaluate regional lung ventilation distribution in patients suffering from chronic heart failure (chf) after completing inspiratory muscle training (imt) and correlate it with functional capacity and quality of life among these individuals. methods and results: nineteen chf patients were randomly assigned to two groups: control and imt. before and after muscle training, subjects were submitted to assessment protocol for respiratory muscles, digital spirometry, optoelectronic plethysmography (oep), the six-minute walk test (6mwt) and a quality of life questionnaire (mlhfq). there was no difference in lung function following the 12-week training period in either group. however, the imt group showed an increase in actual and predicted mip, higher mlfhq score and greater distance walked in the 6mwt, as well as a reduction in the borg scale after the 6 mwt in relation to the control. for the oep, imt group members exhibited higher values for total chest wall volume (vcw), abdominal rib cage volume (vrc,a) and abdominal volume (vab) when compared to the control. conclusions: for patients with chf, imt proved efficient in improving muscle strength, functional capacity and quality of life. the present study also analyzed the distribution behavior of lung volumes for the thoracoabdominal system in this population, showing that larger abdominal rib cage and abdomen volumes may result in more effective diaphragmatic contraction.


Eligibility criteria:
inclusion criteria: * sedentary adults diagnosed with functional class ii and ii chf in accordance with the new york heart association (nyha); * in stage b or c according to american college of sports medicine guidelines; * with left ventricle ejection fraction lower than 45% (evaluated by echocardiogram in a period ≤ 1 year); * cardiomegaly confirmed by increased left ventricle end-diastolic (lvdd) and end-systolic diameter (lvesd) associated with a cardiac index (ci) \>0.5 according to chest x-rays; * inspiratory muscle weakness (mip \<70% of predicted values); * clinical stability with no change in medication for at least three months and sedentary (no regular physical activity performed in the previous six months or not accumulating 30 minutes or more of moderate physical activity - 3 to 6 mets - on most week days). exclusion criteria: * patients exhibiting unstable angina, myocardial infarction or prior heart surgery up to three months before beginning the investigation; * orthopedic, infectious or chronic metabolic diseases; * treatment with steroids, hormones or chemotherapy; * ratio between forced expiratory volume in one second and forced vital capacity (fev1/fvc) \< 70% of predicted, characterizing an obstructive respiratory disorder; * respiratory diseases, smokers and ex-smokers with a history of cigarettes/day for more than 10 years.

Keywords: heart failure respiratory muscles optoelectronic plethysmography
bioresorbable polymer-coated ees in patients at high bleeding risk undergoing pci followed by 1-month dapt

Conditions: Coronary Artery Disease; Acute Coronary Syndrome

Summary: objective: to evaluate the safety of bioresorbable polymer-coated everolimus-eluting synergy® stent followed by 1-month dual antiplatelet therapy in patients at high-bleeding risk. study population: real world high-bleeding risk (hbr) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions. study size: a total of 1023 patients will be enrolled. study design: prospective, single-arm, multicentre trial, powered for non-inferiority with respect to objective performance criteria (opc). antiplatelet therapy: dual antiplatelet therapy with aspirin 100 mg od and a p2y12 inhibitor for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. in case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a p2y12 inhibitor without aspirin for 30 days. primary endpoint: composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis at 1-year follow-up.


Eligibility criteria:
inclusion criteria: all patients will need to have symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, or acute coronary syndromes (including nste-acs and ste-acs) and presence of one or more coronary artery stenoses \>50% in a native coronary artery or a saphenous bypass graft that treated with one or multiple synergy® stents. moreover, in order to be included patients will need to meet at least 1 of the following hbr criteria: 1. age ≥75 years 2. oral anticoagulation planned to continue after pci 3. hemoglobin \<11 g/l, 4. transfusion within 4 week before inclusion 5. platelet count \<100'000 6. hospital admission for bleeding in previous 12 months 7. stroke in previous 12 months 8. history of intracerebral hemorrhage 9. severe chronic liver disease 10. creatinine clearance \<40 ml/min 11. cancer in previous 3 years 12. planned major surgery in next 12 months 13. glucocorticoids or nsaid planned for \>30 days after pci 14. expected non-adherence to \>30 days of dual antiplatelet therapy exclusion criteria: 1. cardiogenic shock 2. major active bleeding at the time of pci 3. expected non-adherence with 1 month dapt 4. known intolerance to aspirin, clopidogrel, or ticagrelor 5. inability to provide informed consent 6. currently participating in another trial before reaching first endpoint
vestibulo-ocular reflex function in individuals with chronic motion sensitivity cross-sectional study

Conditions: Motion Sickness

Summary: chronic motion sensitivity refers to a sensation of unwellness caused by physical or discerned motion and has a prevalence of 28% in the general population and it is more common in women (27.3%) compared to men. the investigators theorize that individuals with chronic motion sensitivity will have an impaired inner ear reflex and will be less physically active. hence, the purpose of this study is to; 1. determine whether the function of an inner ear reflex is different between young adults with/without chronic motion sensitivity 2. assess relationships between reflex function and balance in young adults with/without cms 3. assess relationships between physical activity and balance in young adults with/without cms.

chronic motion sensitivity (cms), also known as motion sickness, refers to a sensation of unwellness caused by physical or discerned motion. cms has a prevalence of 28% in the general population and it is more common in women (27.3%) compared to men. based on established evidence that individuals with chronic motion sensitivity demonstrate impaired postural stability with vestibular system impairment adjudged to be an inciting stimulus for chronic motion sensitivity, and individuals who practiced more physical and sporting activities have less motion sickness susceptibility than individuals who did not, the investigators theorize that individuals with chronic motion sensitivity will have an impaired inner ear reflex, causing them to be more reliant on other sensory systems like their muscles and joints, and their vision, we also theorize that individuals who are physically active will be less susceptible to chronic motion sensitivity. the purpose of this study is to; 1. determine whether the function of an inner ear reflex is different between young adults with/without chronic motion sensitivity 2. assess relationships between reflex function and balance in young adults with/without cms 3. assess relationships between physical activity and balance in young adults with/without cms. participants between the age of 20 and 40 with and without a self-reported history of chronic motion sensitivity (i.e, experiencing nauseousness and/or dizziness during while using various means of transportation such as, car, train, bus, boat, and airplane and/or, recreational fun-fair rides and/or when exposed to conflicting visual images). participants will be excluded if they report a medical diagnosis of central nervous system disorder, impaired cervical spine range of motion, migraines, seizure disorder, vestibular dysfunction, or any musculoskeletal dysfunction that can limit their participation in the study.

Eligibility criteria:
inclusion criteria: * age 20-40 * with and without a history of cms exclusion criteria: * cns disorder * impaired cervical spine rom * migraines * seizures * vestibular dysfunction * musculoskeletal dysfunction * medications causing dizziness

Keywords: chronic motion sensitivity
effects of dry needling on spinal mobility and trigger points in patients with fibromyalgia syndrome.

Conditions: Fibromyalgia; Back Pain

Summary: this study evaluates the effect of dry needling on spinal mobility and trigger points in patients with fibromyalgia syndrome.

dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments. dry needling (dn) is a technique used to treat dysfunctions in skeletal muscle, fascia, and connective tissue, and, diminish persistent peripheral nociceptive input, and reduce or restore impairments of body structure and function leading to improved activity and participation.

Eligibility criteria:
inclusion criteria: * fibromyalgia syndrome diagnosis. * aged from 18 to 65 years. * no regular physical activity. * limitation of usual activities due to pain on at least 1 day in the previous 30 days. * agreement to attend evening therapy sessions. exclusion criteria: * severe physical disability. * comorbid conditions (eg, morbid obesity, inflammatory diseases, irritable bowel syndrome, interstitial cystitis). * uncontrolled endocrine disorders (eg, hyperthyroidism or hypothyroidism, diabetes). * malignancy. * psychiatric. * illnesses (eg, schizophrenia or substance abuse). * medication usage other than as-needed analgesics (excluding long-term narcotics). * history of surgery. * history of whiplash injury. * presence of a score \>9 points in the beck depression inventory.

Keywords: paraspinal muscles trigger points randomized controlled trial mobility limitation
a study of kw-2478 in combination with bortezomib in subjects with relapsed and/or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to assess the safety and benefits of the investigational study drug, kw-2478, when given with bortezomib (velcade®), a drug approved for the treatment of multiple myeloma (mm). the primary objectives: * to establish the safety, tolerability, and recommended phase ii dose (rp2d) of kw-2478 in combination with bortezomib (phase i); * to assess the overall response rate (orr) when subjects with advanced mm are treated (phase ii). the secondary objectives: * to characterize the pharmacokinetic (pk) and pharmacodynamic (pd) of kw-2478 with bortezomib (phase i only); * to evaluate for preliminary evidence of efficacy (phase i); * to determine progression free survival (pfs) and duration of response of kw-2478 with bortezomib (phase ii).

this is a multicenter, open label, dose escalation, phase i / ii study in subjects with relapsed and/or refractory mm. up to 24 subjects to be enrolled in the phase i to determine the rp2d. up to 77 additional evaluable subjects to be enrolled in phase ii for a maximum up to 101 subjects treated in the study. study centers in the usa and the uk will participate in phase i and ii. centers in the philippines will be participating in phase ii only. the planned enrollment period is 22 months and the planned study duration is 28 months.

Eligibility criteria:
accepts healthy volunteers: no inclusion criteria: 1. subjects with a confirmed diagnosis of multiple myeloma who have had one and no more than three prior regimens for mm to which they did not respond (failed) or from which they have relapsed. 2. signed either an irb or iec approved informed consent 3. ecog performance status of ≤ 2 4. life expectancy of at least 3 months 5. m protein in either serum or urine, or free light chains if not measurable m protein in serum or urine, and clonal bone marrow plasma cells \> 10%, and evidence of end organ damage 6. adequate hematologic status, liver and renal function 7. subjects of reproductive potential must agree to follow accepted pregnancy prevention methods during the study. exclusion criteria: 1. no anti-cancer treatment for ≥ 4 weeks and no bortezomib treatment ≥ 60 days prior to receiving study drug 2. any other severe, acute or chronic illness 3. no other prior or concurrent malignancy 4. no immunosuppressant therapy

Keywords: leukemia immunoproliferative disorder neoplasma by histologic type immune system diseases hematologic diseases blood protein disorders paraproteinemias multiple myeloma hematologic disorders leukemia, chronic, b-cell leukemia, b-cell leukemia, chronic neoplasms, plasma cell monoclonal gammopathy of unknown significance (mgus)
enhanced algorithm for crohn's treatment incorporating early combination therapy

Conditions: Crohn's Disease

Summary: assess if the implementation of an enhanced treatment algorithm will improve the management crohn's disease compared to a conventional step-care approach.

crohn's disease (cd) is a chronic inflammatory disorder of the gastrointestinal tract. during disease exacerbations, pharmacological or surgical intervention is usually needed to re-establish remission. ideally, strategies should be employed to maintain patients in long-term remission while minimizing exposure to corticosteroids and reduce therapy-related toxicity. nevertheless, in reality many patients with cd do not receive effective therapy and their disease often remains active, leading to uncontrolled inflammation and complications from either the underlying disease or corticosteroids.

Eligibility criteria:
inclusion criteria: * documented diagnosis of cd * written informed consent must be obtained and documented. * willing to utilize study supply of adalimumab provided in syringe format, if indicated according to treatment algorithm. exclusion criteria: * any conditions (e.g., history of alcohol or substance abuse) which, in the opinion of the investigator, may interfere with the patient's ability to comply with study procedures. * latex allergy or other conditions in which adalimumab syringes are contraindicated * currently participating, or planning to participate in a study involving investigational product within 24 months that may interfere with the patient's ability to comply with study procedures. * previously failed all classes of tumor necrosis factor (tnf) antagonists for the treatment of cd. * diagnosis of short bowel syndrome

Keywords: crohn's disease deep remission complications